ClinicalTrials.gg
Active, not recruitingNCT07212751CT-PLAQUEUpdated Nov 9, 2026

Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)

An observational study in Nonfatal Stroke, Nonfatal Myocardial Infarction and Cardiovascular Death, sponsored by The University of Hong Kong. Active, not recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by The University of Hong Kong · Observational

How we know

Updated Nov 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
22,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by The University of Hong Kong — 4 open to participants now, 5 under way, none of them phase 3. Stroke · The University of Hong Kong.

Started
2020
the only one that year
Observational
3 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Stroke by The University of Hong Kong, this one is the only one that started in 2020, is one of 3 observational ones, and was the 18th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 18 studies in Stroke by The University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by The University of Hong Kong, or all of them as a file.
02

Study summary

The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.

03

Conditions studied

  • Nonfatal Stroke
  • Nonfatal Myocardial Infarction
  • Cardiovascular Death
  • All-cause Death
  • Stroke (Subacute)
  • CT Plaque
  • Calcified Plaque
  • Non-calcified Plaque
  • FFR-CT

Keywords

  • CTCA
  • CT
  • Coronary CT
  • Calcium Score
  • Plaque
  • Coronary Artery Disease
  • CAD
  • Chest pain
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

28000

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
  • If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Exclusion criteria

Exclusion Criteria:

  • Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated \<30 mL/min), major allergy to contrast.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
22,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment

    Diagnostic Test: CTCA

Interventions

  • Diagnostic testCTCA

    Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment \- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

06

What researchers measure

Primary outcomes

  1. Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death

    Time frame: 5 years after CTCA examinations

Secondary outcomes

  1. Total plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  2. Calcified plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  3. Non-calcified plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  4. CT-FFR to predict cardiac events

    Time frame: 5 years after CTCA examinations

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2020 (actual). Primary completion is estimated for Dec 2027, 95 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2027, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Oct 8, 2025
StartActual
Jan 29, 2020
Primary completionEst.
Dec 31, 2027was Jun 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Dec 31, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jun 30, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07212751
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Jan 29, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion